Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children's Hospital, however, are looking into how those same types of common viruses can actually help treat a child who is diagnosed with certain cancers.
Researchers have found that apoptosis, a natural process of programmed cell death, can reactivate latent herpesviruses in the dying cell. The results of their research, which could have broad clinical significance since many cancer chemotherapies cause apoptosis, was published ahead of print in the Journal of Virology.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced that it has treated the first cohort of patients in its Phase I/IIa clinical study of its oncolytic virus, SEPREHVIR (HSV1716) for the treatment of malignant pleural mesothelioma.
The virus that causes those painful lip blisters known as cold sores has an internal pressure eight times higher than a car tire, and uses it to literally blast its infectious DNA into human cells, scientists are reporting in a new study.
Researchers at the University of California, San Diego School of Medicine and colleagues report that the herpes simplex virus type-1 (HSV-1), which affects an estimated 50 to 80 percent of all American adults, exploits an immune system receptor to boost its infectivity and ability to cause disease.
Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.
The University of Illinois at Chicago's Center for Clinical and Translational Science has selected six research projects to receive pilot grants in 2013.
Fred Hutchinson Cancer Research Center and University of Washington scientists have identified a class of immune cells that reside long-term in the genital skin and mucosa and are believed to be responsible for suppressing recurring outbreaks of genital herpes.
Circumcision drastically alters the microbiome of the penis, changes that could explain why circumcision offers protection against HIV and other viral infections.
Jewish leaders this week pointed to a recent independent study by Penn Medicine at the University of Pennsylvania that found little evidence to support the claim that a circumcision practice known as Metzitzah B'Peh (MBP) leads to an increased likelihood of herpes in infants.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Acyclovir Ointment USP, 5%.
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a novel strategy for preventing infections due to the highly common herpes simplex viruses, the microbes responsible for causing genital herpes (herpes simplex virus 2) and cold sores (herpes simplex virus 1).
Severe chronic pain associated with conditions such as bladder pain syndrome/interstitial cystitis often require the use of opioid medication, with the risk of dependency and serious adverse reactions.
Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.
CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.
Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected.
There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?
New research suggests that just one or two individual herpes virus particles attack a skin cell in the first stage of an outbreak, resulting in a bottleneck in which the infection may be vulnerable to medical treatment.
Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE- Open Innovation Forum.
Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round.